{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 262,
   "id": "cd365676-8285-4bfc-a1fe-93fd31ff92cb",
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "\n",
    "def read_file(file):\n",
    "\twith open(file, \"r\") as fp:\n",
    "\t    data = json.load(fp)\n",
    "\treturn data\n",
    "    \n",
    "biomarkers = read_file(\"referenced/biomarkers.json\")\n",
    "indications = read_file(\"data/indications.json\")\n",
    "therapies = read_file(\"referenced/therapies.json\")\n",
    "diseases = read_file(\"referenced/diseases.json\")\n",
    "propositions = read_file(\"referenced/propositions.json\")\n",
    "contributions = read_file(\"referenced/contributions.json\")\n",
    "strength = read_file(\"referenced/strengths.json\")\n",
    "documents = read_file(\"data/documents.json\")\n",
    "statements = read_file(\"data/statements.hc.json\")\n",
    "therapy_groups = read_file(\"referenced/therapy_groups.json\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 263,
   "id": "6a751d62-44dd-465a-acc2-1acc8943e634",
   "metadata": {},
   "outputs": [],
   "source": [
    "therapy_lookup = {item[\"id\"]: item for item in therapies}\n",
    "disease_lookup = {item[\"id\"]: item for item in diseases}\n",
    "biomarker_lookup = {item[\"id\"]: item for item in biomarkers}\n",
    "strength_lookup = {item[\"id\"]: item for item in strength}\n",
    "contribution_lookup = {item[\"id\"]: item for item in contributions}\n",
    "document_lookup = {doc[\"id\"]: doc for doc in documents}\n",
    "indication_lookup = {ind[\"id\"]: ind for ind in indications}\n",
    "therapy_groups_lookup = {item[\"id\"]: item for item in therapy_groups}\n",
    "proposition_lookup = {item['id']: item for item in propositions}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 267,
   "id": "56022c16-68c6-4ece-82fa-60a1333372b7",
   "metadata": {},
   "outputs": [],
   "source": [
    "def dereference_propositions(propositions, therapy_lookup, disease_lookup, biomarker_lookup, therapy_groups_lookup):\n",
    "    dereferenced_props = []\n",
    "    for prop in propositions:\n",
    "        prop = prop.copy()\n",
    "\n",
    "        if prop[\"therapy_id\"] != None:\n",
    "            prop[\"therapy\"] = therapy_lookup[prop[\"therapy_id\"]]\n",
    "            prop.pop(\"therapy_id\")\n",
    "        elif prop[\"therapy_group_id\"] != None:\n",
    "            therapy_group = therapy_groups_lookup[prop[\"therapy_group_id\"]]\n",
    "            prop[\"therapy_group\"] = therapy_group\n",
    "            dereferenced_therapiesG = []\n",
    "            for TGid in therapy_group[\"therapies\"]:\n",
    "                dereferenced_therapiesG.append(therapy_lookup[TGid])\n",
    "            prop[\"therapies\"] = dereferenced_therapiesG\n",
    "            prop.pop(\"therapy_group_id\")\n",
    "        else: \n",
    "            print(\"Unexpected input in proposition\")\n",
    "\n",
    "        condition_id = prop.pop(\"conditionQualifier_id\")\n",
    "        prop[\"conditionQualifier\"] = disease_lookup[condition_id]\n",
    "\n",
    "        resolved_biomarkers = []\n",
    "        for bio in prop[\"biomarkers\"]:\n",
    "            resolved_biomarkers.append(biomarker_lookup[bio])\n",
    "        prop[\"biomarkers\"] = resolved_biomarkers\n",
    "\n",
    "        dereferenced_props.append(prop)\n",
    "    return dereferenced_props\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 268,
   "id": "cb939ca0-bf87-46aa-aabd-1fbce5b9594e",
   "metadata": {},
   "outputs": [],
   "source": [
    "#print(dereference_propositions(propositions, therapy_lookup, disease_lookup, biomarker_lookup, therapy_groups_lookup))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 269,
   "id": "7a1f7792-d055-41c8-a827-ae8938925bfd",
   "metadata": {},
   "outputs": [],
   "source": [
    "dereferenced_props = dereference_propositions(propositions, therapy_lookup, disease_lookup, biomarker_lookup, therapy_groups_lookup)\n",
    "dereferenced_prop_lookup = {prop[\"id\"]: prop for prop in dereferenced_props}\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 271,
   "id": "10a52b00-7170-4328-a5b4-3eb202a658ce",
   "metadata": {},
   "outputs": [],
   "source": [
    "def dereference_statements(statements, proposition_lookup, strength_lookup, indication_lookup, contribution_lookup, document_lookup):\n",
    "    dereferenced_statements = []\n",
    "    for state in statements:\n",
    "        state = state.copy()\n",
    "        proposition_id = state[\"proposition_id\"]\n",
    "\n",
    "        if proposition_id == \"\":\n",
    "            print(\"Skipping statement with empty proposition_id, statement_id:\" + str(state[\"id\"]))\n",
    "        elif proposition_id == None:\n",
    "            strength_id = state.pop(\"strength_id\")\n",
    "            state[\"strength\"] = strength_lookup[strength_id]\n",
    "\n",
    "            indication_id = state.pop(\"indication_id\")\n",
    "            state[\"indication\"] = indication_lookup[indication_id]\n",
    "\n",
    "            contributions_resolved = []\n",
    "            for contrib_id in state[\"contributions\"]:\n",
    "                contributions_resolved.append(contribution_lookup[contrib_id])\n",
    "            state[\"contributions\"] = contributions_resolved\n",
    "\n",
    "            documents_resolved = []\n",
    "            for doc_id in state[\"reportedIn\"]:\n",
    "                documents_resolved.append(document_lookup[doc_id])\n",
    "            state[\"reportedIn\"] = documents_resolved\n",
    "\n",
    "            state.pop(\"proposition_id\")\n",
    "            state[\"proposition\"] = None\n",
    "\n",
    "            dereferenced_statements.append(state)\n",
    "\n",
    "        else:\n",
    "            state.pop(\"proposition_id\")\n",
    "            state[\"proposition\"] = proposition_lookup[proposition_id]\n",
    "\n",
    "            strength_id = state.pop(\"strength_id\")\n",
    "            state[\"strength\"] = strength_lookup[strength_id]\n",
    "\n",
    "            indication_id = state.pop(\"indication_id\")\n",
    "            state[\"indication\"] = indication_lookup[indication_id]\n",
    "\n",
    "            contributions_resolved = []\n",
    "            for contrib_id in state[\"contributions\"]:\n",
    "                contributions_resolved.append(contribution_lookup[contrib_id])\n",
    "            state[\"contributions\"] = contributions_resolved \n",
    "\n",
    "            documents_resolved = []\n",
    "            for doc_id in state[\"reportedIn\"]:\n",
    "                documents_resolved.append(document_lookup[doc_id])\n",
    "            state[\"reportedIn\"] = documents_resolved\n",
    "\n",
    "            dereferenced_statements.append(state)\n",
    "            \n",
    "    return dereferenced_statements\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 273,
   "id": "fb0c9eaf-d5b1-4b55-8756-80435bde4291",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Skipping statement with empty proposition_id, statement_id:hc:97\n",
      "Skipping statement with empty proposition_id, statement_id:hc:98\n",
      "Skipping statement with empty proposition_id, statement_id:hc:99\n",
      "Skipping statement with empty proposition_id, statement_id:hc:100\n",
      "Skipping statement with empty proposition_id, statement_id:hc:101\n",
      "Skipping statement with empty proposition_id, statement_id:hc:102\n",
      "Skipping statement with empty proposition_id, statement_id:hc:103\n",
      "Skipping statement with empty proposition_id, statement_id:hc:104\n",
      "Skipping statement with empty proposition_id, statement_id:hc:105\n",
      "[{'id': 'hc:0', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.adcetris', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Adcetris (brentuximab vedotin) [product monograph]. HC.', 'aliases': [], 'citation': 'Seagen Inc. Adcetris (brentuximab vedotin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080158.PDF. Published April 2025. Accessed June 2025.', 'company': 'Seagen Inc.', 'drug_name_brand': 'Adcetris', 'drug_name_generic': 'brentuximab vedotin', 'first_published': None, 'access_date': '2025-06-11', 'organization_id': 'hc', 'publication_date': '2025-04-08', 'url': 'https://pdf.hres.ca/dpd_pm/00080158.PDF', 'url_drug': 'https://healetslth-products.canada.ca/dpd-bdpp/info?lang=eng&code=88626', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 48, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [0], 'conditionQualifier_id': 3, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 11}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.adcetris:0', 'document_id': 'doc:hc.adcetris', 'indication': 'ADCETRIS is indicated for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30.', 'raw_biomarkers': 'CD30-expressing', 'raw_cancer_type': 'systemic anaplastic large cell lymphoma (sALCL), CD30-expression peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), CD30-expression angioimmunoblastic T-cell lymphoma (AITL)', 'raw_therapeutics': 'Adcetris (brentuximab vedotin), cyclophosphamide, doxorubicin, and prednisone (CHP)'}}, {'id': 'hc:26', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.adcetris', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Adcetris (brentuximab vedotin) [product monograph]. HC.', 'aliases': [], 'citation': 'Seagen Inc. Adcetris (brentuximab vedotin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080158.PDF. Published April 2025. Accessed June 2025.', 'company': 'Seagen Inc.', 'drug_name_brand': 'Adcetris', 'drug_name_generic': 'brentuximab vedotin', 'first_published': None, 'access_date': '2025-06-11', 'organization_id': 'hc', 'publication_date': '2025-04-08', 'url': 'https://pdf.hres.ca/dpd_pm/00080158.PDF', 'url_drug': 'https://healetslth-products.canada.ca/dpd-bdpp/info?lang=eng&code=88626', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 48, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [0], 'conditionQualifier_id': 3, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 11}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.adcetris:0', 'document_id': 'doc:hc.adcetris', 'indication': 'ADCETRIS is indicated for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30.', 'raw_biomarkers': 'CD30-expressing', 'raw_cancer_type': 'systemic anaplastic large cell lymphoma (sALCL), CD30-expression peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), CD30-expression angioimmunoblastic T-cell lymphoma (AITL)', 'raw_therapeutics': 'Adcetris (brentuximab vedotin), cyclophosphamide, doxorubicin, and prednisone (CHP)'}}, {'id': 'hc:27', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.adcetris', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Adcetris (brentuximab vedotin) [product monograph]. HC.', 'aliases': [], 'citation': 'Seagen Inc. Adcetris (brentuximab vedotin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080158.PDF. Published April 2025. Accessed June 2025.', 'company': 'Seagen Inc.', 'drug_name_brand': 'Adcetris', 'drug_name_generic': 'brentuximab vedotin', 'first_published': None, 'access_date': '2025-06-11', 'organization_id': 'hc', 'publication_date': '2025-04-08', 'url': 'https://pdf.hres.ca/dpd_pm/00080158.PDF', 'url_drug': 'https://healetslth-products.canada.ca/dpd-bdpp/info?lang=eng&code=88626', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 48, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [0], 'conditionQualifier_id': 3, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 11}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.adcetris:0', 'document_id': 'doc:hc.adcetris', 'indication': 'ADCETRIS is indicated for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30.', 'raw_biomarkers': 'CD30-expressing', 'raw_cancer_type': 'systemic anaplastic large cell lymphoma (sALCL), CD30-expression peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), CD30-expression angioimmunoblastic T-cell lymphoma (AITL)', 'raw_therapeutics': 'Adcetris (brentuximab vedotin), cyclophosphamide, doxorubicin, and prednisone (CHP)'}}, {'id': 'hc:1', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.adcetris', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Adcetris (brentuximab vedotin) [product monograph]. HC.', 'aliases': [], 'citation': 'Seagen Inc. Adcetris (brentuximab vedotin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080158.PDF. Published April 2025. Accessed June 2025.', 'company': 'Seagen Inc.', 'drug_name_brand': 'Adcetris', 'drug_name_generic': 'brentuximab vedotin', 'first_published': None, 'access_date': '2025-06-11', 'organization_id': 'hc', 'publication_date': '2025-04-08', 'url': 'https://pdf.hres.ca/dpd_pm/00080158.PDF', 'url_drug': 'https://healetslth-products.canada.ca/dpd-bdpp/info?lang=eng&code=88626', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 836, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [0], 'conditionQualifier_id': 89, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 11}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.adcetris:1', 'document_id': 'doc:hc.adcetris', 'indication': 'ADCETRIS is indicated for the treatment of adult patients with CD30-expressing MF who have received prio systemic therapy', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved brentuximab vedotin for the treatment of adult patients with CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.', 'raw_biomarkers': 'CD30-expressing', 'raw_cancer_type': 'CD30-Expressing Mycosis Fungoides (MF)', 'raw_therapeutics': 'Adcetris (brentuximab vedotin)'}}, {'id': 'hc:2', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.afinitor', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Afinitor (everolimus) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Afinitor (everolimus) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00063824.PDF. Revised November 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Afinitor', 'drug_name_generic': 'everolimus', 'first_published': '2009-12-11', 'access_date': '2025-06-11', 'organization_id': 'hc', 'publication_date': '2021-11-30', 'url': 'https://pdf.hres.ca/dpd_pm/00063824.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82511', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 131, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [1, 2], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 26}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.afinitor:0', 'document_id': 'doc:hc.afinitor', 'indication': 'AFINITOR is indicated for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer in combination with exemestane after recurrence or progression following treatment with letrozole or anastrozole.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved everolimus in combination with exemestane for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer after recurrence or progression following treatment with letrozole or anastrozole.', 'raw_biomarkers': 'HR+, HER2-negative', 'raw_cancer_type': 'advanced breast cancer', 'raw_therapeutics': 'Afinitor (everolimus) in combination with exemestane'}}, {'id': 'hc:3', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.afinitor', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Afinitor (everolimus) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Afinitor (everolimus) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00063824.PDF. Revised November 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Afinitor', 'drug_name_generic': 'everolimus', 'first_published': '2009-12-11', 'access_date': '2025-06-11', 'organization_id': 'hc', 'publication_date': '2021-11-30', 'url': 'https://pdf.hres.ca/dpd_pm/00063824.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82511', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 132, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [2, 3], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 26}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.afinitor:0', 'document_id': 'doc:hc.afinitor', 'indication': 'AFINITOR is indicated for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer in combination with exemestane after recurrence or progression following treatment with letrozole or anastrozole.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved everolimus in combination with exemestane for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer after recurrence or progression following treatment with letrozole or anastrozole.', 'raw_biomarkers': 'HR+, HER2-negative', 'raw_cancer_type': 'advanced breast cancer', 'raw_therapeutics': 'Afinitor (everolimus) in combination with exemestane'}}, {'id': 'hc:28', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.afinitor', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Afinitor (everolimus) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Afinitor (everolimus) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00063824.PDF. Revised November 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Afinitor', 'drug_name_generic': 'everolimus', 'first_published': '2009-12-11', 'access_date': '2025-06-11', 'organization_id': 'hc', 'publication_date': '2021-11-30', 'url': 'https://pdf.hres.ca/dpd_pm/00063824.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82511', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 133, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [1, 2, 3], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 26}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.afinitor:0', 'document_id': 'doc:hc.afinitor', 'indication': 'AFINITOR is indicated for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer in combination with exemestane after recurrence or progression following treatment with letrozole or anastrozole.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved everolimus in combination with exemestane for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer after recurrence or progression following treatment with letrozole or anastrozole.', 'raw_biomarkers': 'HR+, HER2-negative', 'raw_cancer_type': 'advanced breast cancer', 'raw_therapeutics': 'Afinitor (everolimus) in combination with exemestane'}}, {'id': 'hc:4', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.alecensaro', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Alecensaro (alectinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Alecensaro (alectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078825.PDF. Revised March 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Alecensaro', 'drug_name_generic': 'alectinib', 'first_published': '2016-09-29', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2025-03-11', 'url': 'https://pdf.hres.ca/dpd_pm/00078825.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 22, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [8], 'conditionQualifier_id': 47, 'subjectVariant': {}, 'therapy_id': 9, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.alecensaro:0', 'document_id': 'doc:hc.alecensaro', 'indication': 'ALECENSARO (alectinib) is indicated for the first-line treatment of patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved alectinib for the first-line treatment of patients with ALK-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) that is not amenable to curative therapy.', 'raw_biomarkers': 'ALK-positive', 'raw_cancer_type': 'metastatic non-small cell lung cancer', 'raw_therapeutics': 'Alecensaro (alectinib)'}}, {'id': 'hc:5', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.alunbrig', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Alunbrig (brigatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Takeda Canada Inc. Alunbrig (brigatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00066731.PDF. Revised July 2022. Accessed June 2025.', 'company': 'Takeda Canada Inc.', 'drug_name_brand': 'Alunbrig', 'drug_name_generic': 'brigatinib', 'first_published': '2018-07-25', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2022-07-19', 'url': 'https://pdf.hres.ca/dpd_pm/00066731.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96982', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 50, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [8], 'conditionQualifier_id': 47, 'subjectVariant': {}, 'therapy_id': 10, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.alunbrig:0', 'document_id': 'doc:hc.alunbrig', 'indication': 'ALUNBRIG (brigatinib) is indicated as a monotherapy for the first line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved brigatinib as monotherapy for the first-line treatment of adult patients with ALK-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) that is not amenable to curative therapy.', 'raw_biomarkers': 'ALK-positive', 'raw_cancer_type': 'metastatic non-small cell lung cancer', 'raw_therapeutics': 'Alunbrig (brigatinib)'}}, {'id': 'hc:6', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.augtyro', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Augtyro (repotrectinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Bristol-Myers Squibb Canada. Augtyro (repotrectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080483.PDF. Published May 2024. Accessed June 2025.', 'company': 'Bristol-Myers Squibb Canada', 'drug_name_brand': 'Augtyro', 'drug_name_generic': 'repotrectinib', 'first_published': '2025-05-07', 'access_date': '2025-06-23', 'organization_id': 'hc', 'publication_date': '2025-05-07', 'url': 'https://pdf.hres.ca/dpd_pm/00080483.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106076', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 368, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [62], 'conditionQualifier_id': 47, 'subjectVariant': {}, 'therapy_id': 134, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.augtyro:0', 'document_id': 'doc:hc.augtyro', 'indication': 'AUGTYRO (repotrectinib capsules) is indicated for treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved repotrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).', 'raw_biomarkers': 'ROS1-positive', 'raw_cancer_type': 'locally advanced or metastatic non-small cell lung cancer', 'raw_therapeutics': 'Augtyro (repotrectinib)'}}, {'id': 'hc:7', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.balversa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Balversa (erdafitinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Janssen Inc. Balversa (erdafitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077812.PDF. Revised November 2024. Accessed June 2025.', 'company': 'Janssen Inc.', 'drug_name_brand': 'Balversa', 'drug_name_generic': 'erdafitinib', 'first_published': '2019-10-25', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-11-20', 'url': 'https://pdf.hres.ca/dpd_pm/00077812.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98320', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 124, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [99], 'conditionQualifier_id': 8, 'subjectVariant': {}, 'therapy_id': 110, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.balversa:0', 'document_id': 'doc:hc.balversa', 'indication': 'BALVERSA (erdafitinib) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, who have disease progression during or following at least one line of prior therapy including within 12 months of neoadjuvant or adjuvant therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC) harboring susceptible FGFR3 genetic alterations, who have experienced disease progression during or after at least one line of prior therapy, including within 12 months of neoadjuvant or adjuvant therapy.', 'raw_biomarkers': 'susceptible FGFR3 genetic alterations', 'raw_cancer_type': 'locally advanced unresectable or metastatic urothelial carcinoman (UC)', 'raw_therapeutics': 'Balversa (erdafitinib)'}}, {'id': 'hc:8', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.balversa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Balversa (erdafitinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Janssen Inc. Balversa (erdafitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077812.PDF. Revised November 2024. Accessed June 2025.', 'company': 'Janssen Inc.', 'drug_name_brand': 'Balversa', 'drug_name_generic': 'erdafitinib', 'first_published': '2019-10-25', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-11-20', 'url': 'https://pdf.hres.ca/dpd_pm/00077812.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98320', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 125, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [100], 'conditionQualifier_id': 8, 'subjectVariant': {}, 'therapy_id': 110, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.balversa:0', 'document_id': 'doc:hc.balversa', 'indication': 'BALVERSA (erdafitinib) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, who have disease progression during or following at least one line of prior therapy including within 12 months of neoadjuvant or adjuvant therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC) harboring susceptible FGFR3 genetic alterations, who have experienced disease progression during or after at least one line of prior therapy, including within 12 months of neoadjuvant or adjuvant therapy.', 'raw_biomarkers': 'susceptible FGFR3 genetic alterations', 'raw_cancer_type': 'locally advanced unresectable or metastatic urothelial carcinoman (UC)', 'raw_therapeutics': 'Balversa (erdafitinib)'}}, {'id': 'hc:9', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.balversa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Balversa (erdafitinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Janssen Inc. Balversa (erdafitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077812.PDF. Revised November 2024. Accessed June 2025.', 'company': 'Janssen Inc.', 'drug_name_brand': 'Balversa', 'drug_name_generic': 'erdafitinib', 'first_published': '2019-10-25', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-11-20', 'url': 'https://pdf.hres.ca/dpd_pm/00077812.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98320', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 126, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [101], 'conditionQualifier_id': 8, 'subjectVariant': {}, 'therapy_id': 110, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.balversa:0', 'document_id': 'doc:hc.balversa', 'indication': 'BALVERSA (erdafitinib) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, who have disease progression during or following at least one line of prior therapy including within 12 months of neoadjuvant or adjuvant therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC) harboring susceptible FGFR3 genetic alterations, who have experienced disease progression during or after at least one line of prior therapy, including within 12 months of neoadjuvant or adjuvant therapy.', 'raw_biomarkers': 'susceptible FGFR3 genetic alterations', 'raw_cancer_type': 'locally advanced unresectable or metastatic urothelial carcinoman (UC)', 'raw_therapeutics': 'Balversa (erdafitinib)'}}, {'id': 'hc:10', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.balversa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Balversa (erdafitinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Janssen Inc. Balversa (erdafitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077812.PDF. Revised November 2024. Accessed June 2025.', 'company': 'Janssen Inc.', 'drug_name_brand': 'Balversa', 'drug_name_generic': 'erdafitinib', 'first_published': '2019-10-25', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-11-20', 'url': 'https://pdf.hres.ca/dpd_pm/00077812.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98320', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 127, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [102], 'conditionQualifier_id': 8, 'subjectVariant': {}, 'therapy_id': 110, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.balversa:0', 'document_id': 'doc:hc.balversa', 'indication': 'BALVERSA (erdafitinib) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, who have disease progression during or following at least one line of prior therapy including within 12 months of neoadjuvant or adjuvant therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC) harboring susceptible FGFR3 genetic alterations, who have experienced disease progression during or after at least one line of prior therapy, including within 12 months of neoadjuvant or adjuvant therapy.', 'raw_biomarkers': 'susceptible FGFR3 genetic alterations', 'raw_cancer_type': 'locally advanced unresectable or metastatic urothelial carcinoman (UC)', 'raw_therapeutics': 'Balversa (erdafitinib)'}}, {'id': 'hc:11', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.balversa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Balversa (erdafitinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Janssen Inc. Balversa (erdafitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077812.PDF. Revised November 2024. Accessed June 2025.', 'company': 'Janssen Inc.', 'drug_name_brand': 'Balversa', 'drug_name_generic': 'erdafitinib', 'first_published': '2019-10-25', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-11-20', 'url': 'https://pdf.hres.ca/dpd_pm/00077812.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98320', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 128, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [97], 'conditionQualifier_id': 8, 'subjectVariant': {}, 'therapy_id': 110, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.balversa:0', 'document_id': 'doc:hc.balversa', 'indication': 'BALVERSA (erdafitinib) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, who have disease progression during or following at least one line of prior therapy including within 12 months of neoadjuvant or adjuvant therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC) harboring susceptible FGFR3 genetic alterations, who have experienced disease progression during or after at least one line of prior therapy, including within 12 months of neoadjuvant or adjuvant therapy.', 'raw_biomarkers': 'susceptible FGFR3 genetic alterations', 'raw_cancer_type': 'locally advanced unresectable or metastatic urothelial carcinoman (UC)', 'raw_therapeutics': 'Balversa (erdafitinib)'}}, {'id': 'hc:12', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.besponsa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Besponsa (inotuzumab ozogamicin) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Besponsa (inotuzumab ozogamicin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077730.PDF. Revised November 2024. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Besponsa', 'drug_name_generic': 'inotuzumab ozogamicin', 'first_published': '2018-03-15', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-11-08', 'url': 'https://pdf.hres.ca/dpd_pm/00077730.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96383', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 168, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [13], 'conditionQualifier_id': 0, 'subjectVariant': {}, 'therapy_id': 14, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.besponsa:0', 'document_id': 'doc:hc.besponsa', 'indication': 'BESPONSA (inotuzumab ozogamicin for injection) is indicated for monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved inotuzumab ozogamicin as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).', 'raw_biomarkers': 'CD22-positive', 'raw_cancer_type': 'B-cell precursor acute lymphoblastic leukemia', 'raw_therapeutics': 'Besponsa (inotuzumab ozogamicin)'}}, {'id': 'hc:13', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.blincyto', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Blincyto (blinatumomab) [product monograph]. HC.', 'aliases': [], 'citation': 'Amgen Canada Inc. Blincyto (blinatumomab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078156.PDF. Revised December 2024. Accessed June 2025.', 'company': 'Amgen Canada Inc.', 'drug_name_brand': 'Blincyto', 'drug_name_generic': 'blinatumomab', 'first_published': '2015-12-22', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-12-27', 'url': 'https://pdf.hres.ca/dpd_pm/00078156.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93642', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 45, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [14], 'conditionQualifier_id': 0, 'subjectVariant': {}, 'therapy_id': 15, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.blincyto:2', 'document_id': 'doc:hc.blincyto', 'indication': 'BLINCYTO (blinatumomab for injection) is indicated for the treatment of adult patients with relapsed or refractory B-cell precursor ALL.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved blinatumomab for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).', 'raw_biomarkers': 'CD19-positive', 'raw_cancer_type': 'B-cell precursor acute lymphoblastic leukemia (ALL)', 'raw_therapeutics': 'Blincyto (blinatumomab)'}}, {'id': 'hc:13', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.bosulif', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Bosulif (bosutinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Bosulif (bosutinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076285.PDF. Revised July 2024. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Bosulif', 'drug_name_generic': 'bosutinib', 'first_published': '2014-03-07', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-07-12', 'url': 'https://pdf.hres.ca/dpd_pm/00076285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90368', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 47, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [12], 'conditionQualifier_id': 13, 'subjectVariant': {}, 'therapy_id': 16, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.bosulif:0', 'document_id': 'doc:hc.bosulif', 'indication': 'BOSULIF (bosutinib) is indicated for the treatment of adult patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved bosutinib for the treatment of adult patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML).', 'raw_biomarkers': 'philadelphia chromosome-positive (Ph+)', 'raw_cancer_type': 'chronic myelogenous leukemia', 'raw_therapeutics': 'Bosulif (bosutinib)'}}, {'id': 'hc:14', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.bosulif', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Bosulif (bosutinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Bosulif (bosutinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076285.PDF. Revised July 2024. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Bosulif', 'drug_name_generic': 'bosutinib', 'first_published': '2014-03-07', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-07-12', 'url': 'https://pdf.hres.ca/dpd_pm/00076285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90368', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 47, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [12], 'conditionQualifier_id': 13, 'subjectVariant': {}, 'therapy_id': 16, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.bosulif:1', 'document_id': 'doc:hc.bosulif', 'indication': 'BOSULIF (bosutinib) is indicated for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adult patients with resistance or intolerance to prior TKI therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved bosutinib for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adult patients with resistance or intolerance to prior TKI therapy.', 'raw_biomarkers': 'philadelphia chromosone-positive (Ph+)', 'raw_cancer_type': 'chronic myelogenous leukemia', 'raw_therapeutics': 'Bosulif (bosutinib)'}}, {'id': 'hc:15', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.braftovi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Braftovi (encorafenib) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Braftovi (encorafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074711.PDF. Revised February 2024. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Braftovi', 'drug_name_generic': 'encorafenib', 'first_published': '2021-03-02', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-02-23', 'url': 'https://pdf.hres.ca/dpd_pm/00074711.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 41, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [16], 'conditionQualifier_id': 40, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 10}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.braftovi:0', 'document_id': 'doc:hc.', 'indication': 'BRAFTOVI (encorafenib) is indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved encorafenib in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.', 'raw_biomarkers': 'BRAF V600E or BRAF V600K', 'raw_cancer_type': 'unresectable or metastatic melanoma', 'raw_therapeutics': 'Braftovi (encorafenib) in combination with binimetinib'}}, {'id': 'hc:16', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.braftovi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Braftovi (encorafenib) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Braftovi (encorafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074711.PDF. Revised February 2024. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Braftovi', 'drug_name_generic': 'encorafenib', 'first_published': '2021-03-02', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-02-23', 'url': 'https://pdf.hres.ca/dpd_pm/00074711.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.braftovi:1', 'document_id': 'doc:hc.braftovi', 'indication': 'BRAFTOVI (encorafenib) is indicated, in combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, after prior therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved encorafenib in combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, after prior therapy.', 'raw_biomarkers': 'BRAF V600E', 'raw_cancer_type': 'metastatic colorectal cancer (mCRC)', 'raw_therapeutics': 'Braftovi (encorafenib) in combination with cetuximab'}, 'proposition': None}, {'id': 'hc:17', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.braftovi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Braftovi (encorafenib) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Braftovi (encorafenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074711.PDF. Revised February 2024. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Braftovi', 'drug_name_generic': 'encorafenib', 'first_published': '2021-03-02', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-02-23', 'url': 'https://pdf.hres.ca/dpd_pm/00074711.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 81, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [16], 'conditionQualifier_id': 15, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 16}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.braftovi:1', 'document_id': 'doc:hc.braftovi', 'indication': 'BRAFTOVI (encorafenib) is indicated, in combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, after prior therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved encorafenib in combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, after prior therapy.', 'raw_biomarkers': 'BRAF V600E', 'raw_cancer_type': 'metastatic colorectal cancer (mCRC)', 'raw_therapeutics': 'Braftovi (encorafenib) in combination with cetuximab'}}, {'id': 'hc:18', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.cotellic', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Cotellic (cobimetinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Cotellic (cobimetinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070061.PDF. Revised March 2023. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Cotellic', 'drug_name_generic': 'cobimetinib', 'first_published': '2016-02-22', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2023-03-24', 'url': 'https://pdf.hres.ca/dpd_pm/00070061.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 82, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [16], 'conditionQualifier_id': 40, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 17}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.cotellic:0', 'document_id': 'doc:hc.cotellic', 'indication': 'COTELLIC (cobimetinib) is indicated for use in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved cobimetinib in combination wih vemurafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.', 'raw_biomarkers': 'BRAF V600 mutation', 'raw_cancer_type': 'unresectable or metastatic melanoma', 'raw_therapeutics': 'Cotellic in combination with vemurafenib'}}, {'id': 'hc:19', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.cotellic', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Cotellic (cobimetinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Cotellic (cobimetinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00070061.PDF. Revised March 2023. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Cotellic', 'drug_name_generic': 'cobimetinib', 'first_published': '2016-02-22', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2023-03-24', 'url': 'https://pdf.hres.ca/dpd_pm/00070061.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 83, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [17], 'conditionQualifier_id': 40, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 17}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.cotellic:0', 'document_id': 'doc:hc.cotellic', 'indication': 'COTELLIC (cobimetinib) is indicated for use in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved cobimetinib in combination wih vemurafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.', 'raw_biomarkers': 'BRAF V600 mutation', 'raw_cancer_type': 'unresectable or metastatic melanoma', 'raw_therapeutics': 'Cotellic in combination with vemurafenib'}}, {'id': 'hc:20', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.enhertu', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Enhertu (trastuzumab deruxtecan) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Enhertu (trastuzumab deruxtecan) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078361.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Enhertu', 'drug_name_generic': 'trastuzumab deruxtecan', 'first_published': '2021-04-15', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-01-17', 'url': 'https://pdf.hres.ca/dpd_pm/00078361.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100355', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 420, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [20], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': 26, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.enhertu:0', 'document_id': 'doc:hc.enhertu', 'indication': 'ENHERTU (trastuzumab deruxtecan for injection) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received at least one prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received at least one prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy.', 'raw_biomarkers': 'HER2-positive', 'raw_cancer_type': 'unresectable or metastatic breast cancer', 'raw_therapeutics': 'Enhertu (trastuzumab deruxtecan)'}}, {'id': 'hc:21', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.enhertu', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Enhertu (trastuzumab deruxtecan) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Enhertu (trastuzumab deruxtecan) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078361.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Enhertu', 'drug_name_generic': 'trastuzumab deruxtecan', 'first_published': '2021-04-15', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-01-17', 'url': 'https://pdf.hres.ca/dpd_pm/00078361.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100355', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 420, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [20], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': 26, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.enhertu:1', 'document_id': 'doc:hc.enhertu', 'indication': 'ENHERTU (trastuzumab deruxtecan for injection) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received prior treatment with trastuzumab emtansine (T-DM1).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received prior treatment with trastuzumab emtansine (T-DM1).', 'raw_biomarkers': 'HER2-positive', 'raw_cancer_type': 'unresectable or metastatic breast cancer', 'raw_therapeutics': 'Enhertu (trastuzumab deruxtecan)'}}, {'id': 'hc:22', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.enhertu', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Enhertu (trastuzumab deruxtecan) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Enhertu (trastuzumab deruxtecan) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078361.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Enhertu', 'drug_name_generic': 'trastuzumab deruxtecan', 'first_published': '2021-04-15', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-01-17', 'url': 'https://pdf.hres.ca/dpd_pm/00078361.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100355', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 421, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [22], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': 26, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.enhertu:0', 'document_id': 'doc:hc.enhertu', 'indication': 'ENHERTU (trastuzumab deruxtecan for injection) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received at least one prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received at least one prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy.', 'raw_biomarkers': 'HER2-positive', 'raw_cancer_type': 'unresectable or metastatic breast cancer', 'raw_therapeutics': 'Enhertu (trastuzumab deruxtecan)'}}, {'id': 'hc:23', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.enhertu', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Enhertu (trastuzumab deruxtecan) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Enhertu (trastuzumab deruxtecan) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078361.PDF. Revised January 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Enhertu', 'drug_name_generic': 'trastuzumab deruxtecan', 'first_published': '2021-04-15', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-01-17', 'url': 'https://pdf.hres.ca/dpd_pm/00078361.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100355', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 423, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [20], 'conditionQualifier_id': 2, 'subjectVariant': {}, 'therapy_id': 26, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.enhertu:3', 'document_id': 'doc:hc.enhertu', 'indication': 'ENHERTU (trastuzumab deruxtecan) as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with unresectable,locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.', 'raw_biomarkers': 'HER2-positive', 'raw_cancer_type': 'unresectable locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma', 'raw_therapeutics': 'Enhertu (trastuzumab deruxtecan)'}}, {'id': 'hc:24', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.erbitux', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Erbitux (cetuximab) [product monograph]. HC.', 'aliases': [], 'citation': 'ImClone LLC. Erbitux (cetuximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00043071.PDF. Published January 2018. Accessed June 2025.', 'company': 'ImClone LLC', 'drug_name_brand': 'Erbitux', 'drug_name_generic': 'cetuximab', 'first_published': '2018-01-10', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2018-01-10', 'url': 'https://pdf.hres.ca/dpd_pm/00043071.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75672', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 78, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [24, 25], 'conditionQualifier_id': 15, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 14}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.erbitux:0', 'document_id': 'doc:hc.erbitux', 'indication': 'ERBITUX (cetuximab) is indicated for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) for first-line treatment.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved cetuximab for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) for first-line treatment.', 'raw_biomarkers': 'EGFR-expressing, K-Ras wild type', 'raw_cancer_type': 'metastatic colorectal carcinoma (mCRC)', 'raw_therapeutics': 'Erbitux (cetuximab) in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin)'}}, {'id': 'hc:25', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.erbitux', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Erbitux (cetuximab) [product monograph]. HC.', 'aliases': [], 'citation': 'ImClone LLC. Erbitux (cetuximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00043071.PDF. Published January 2018. Accessed June 2025.', 'company': 'ImClone LLC', 'drug_name_brand': 'Erbitux', 'drug_name_generic': 'cetuximab', 'first_published': '2018-01-10', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2018-01-10', 'url': 'https://pdf.hres.ca/dpd_pm/00043071.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75672', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 79, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [24, 25], 'conditionQualifier_id': 15, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 15}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.erbitux:1', 'document_id': 'doc:hc.erbitux', 'indication': 'ERBITUX (cetuximab) is indicated for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in combination with irinotecan in patients who are refractory to other irinotecan-based chemotherapy regimens.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved cetuximab for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in combination with irinotecan in patients who are refractory to other irinotecan-based chemotherapy regimens.', 'raw_biomarkers': 'EGFR-expressing, K-Ras wild type', 'raw_cancer_type': 'metastatic colorectal carcinoma (mCRC)', 'raw_therapeutics': 'Erbitux (cetuximab) in combination with irinotecan'}}, {'id': 'hc:29', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.erbitux', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Erbitux (cetuximab) [product monograph]. HC.', 'aliases': [], 'citation': 'ImClone LLC. Erbitux (cetuximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00043071.PDF. Published January 2018. Accessed June 2025.', 'company': 'ImClone LLC', 'drug_name_brand': 'Erbitux', 'drug_name_generic': 'cetuximab', 'first_published': '2018-01-10', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2018-01-10', 'url': 'https://pdf.hres.ca/dpd_pm/00043071.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75672', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 80, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [24, 25], 'conditionQualifier_id': 15, 'subjectVariant': {}, 'therapy_id': 19, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.erbitux:2', 'document_id': 'doc:hc.erbitux', 'indication': 'ERBITUX (cetuximab) is indicated as a single agent in patients who are intolerant to irinotecan-based chemotherapy for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved cetuximab as a single agent for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in patients who are intolerant to irinotecan-based chemotherapy.', 'raw_biomarkers': 'EGFR-expressing, K-Ras wild type', 'raw_cancer_type': 'metastatic colorectal carcinoma (mCRC)', 'raw_therapeutics': 'Erbitux (cetuximab) as a single agent'}}, {'id': 'hc:30', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.erbitux', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Erbitux (cetuximab) [product monograph]. HC.', 'aliases': [], 'citation': 'ImClone LLC. Erbitux (cetuximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00043071.PDF. Published January 2018. Accessed June 2025.', 'company': 'ImClone LLC', 'drug_name_brand': 'Erbitux', 'drug_name_generic': 'cetuximab', 'first_published': '2018-01-10', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2018-01-10', 'url': 'https://pdf.hres.ca/dpd_pm/00043071.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75672', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 80, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [24, 25], 'conditionQualifier_id': 15, 'subjectVariant': {}, 'therapy_id': 19, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.erbitux:3', 'document_id': 'doc:hc.erbitux', 'indication': 'ERBITUX (cetuximab) is indicated as a single agent for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in patients who have failed both irinotecan- and oxaliplatin-based regimens and who have received a fluoropyrimidine.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved cetuximab as a single agent for the treatment of EGFR-expressing K-Ras wild-type metastatic colorectal carcinoma (mCRC) in patients who have failed both irinotecan- and oxaliplatin-based regimens and who have received a fluoropyrimidine.', 'raw_biomarkers': 'EGFR-expressing, K-Ras wild type', 'raw_cancer_type': 'metastatic colorectal carcinoma (mCRC)', 'raw_therapeutics': 'Erbitux (cetuximab) as a single agent'}}, {'id': 'hc:31', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.faslodex', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Faslodex (fulvestrant) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Faslodex (fulvestrant) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00053975.PDF. Revised November 2019. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Faslodex', 'drug_name_generic': 'fulvestrant', 'first_published': None, 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-11-15', 'url': 'https://pdf.hres.ca/dpd_pm/00053975.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72981', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 134, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [1, 2], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': 30, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.faslodex:0', 'document_id': 'doc:hc.faslodex', 'indication': 'FASLODEX (fulvestrant) is indicated for the treatment of estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved fulvestrant for the treatment of estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.', 'raw_biomarkers': 'estrogen receptor-positive (ER+), HER2-negative', 'raw_cancer_type': 'locally advanced or metastatic breast cancer', 'raw_therapeutics': 'Faslodex (fulvestrant)'}}, {'id': 'hc:32', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.giotrif', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Giotrif (afatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Boehringer Ingelheim (Canada) Ltd. Giotrif (afatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00051644.PDF. Revised June 2019. Accessed June 2025.', 'company': 'Boehringer Ingelheim (Canada) Ltd', 'drug_name_brand': 'Giotrif', 'drug_name_generic': 'afatinib', 'first_published': None, 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2019-06-06', 'url': 'https://pdf.hres.ca/dpd_pm/00051644.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90026', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 21, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [72], 'conditionQualifier_id': 47, 'subjectVariant': {}, 'therapy_id': 34, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.giotrif:0', 'document_id': 'doc:hc.giotrif', 'indication': 'GIOTRIF (afatinib) is indicated as monotherapy for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor nave patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved afatinib for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor nave patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s).', 'raw_biomarkers': 'EGFR Del 19, EGFR exon 21 L858R', 'raw_cancer_type': 'metastatic adenocarcinoma of the lung', 'raw_therapeutics': 'Giotrif (afatinib)'}}, {'id': 'hc:33', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.giotrif', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Giotrif (afatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Boehringer Ingelheim (Canada) Ltd. Giotrif (afatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00051644.PDF. Revised June 2019. Accessed June 2025.', 'company': 'Boehringer Ingelheim (Canada) Ltd', 'drug_name_brand': 'Giotrif', 'drug_name_generic': 'afatinib', 'first_published': None, 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2019-06-06', 'url': 'https://pdf.hres.ca/dpd_pm/00051644.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90026', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 560, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [19], 'conditionQualifier_id': 47, 'subjectVariant': {}, 'therapy_id': 34, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.giotrif:0', 'document_id': 'doc:hc.giotrif', 'indication': 'GIOTRIF (afatinib) is indicated as monotherapy for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor nave patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved afatinib for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor nave patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s).', 'raw_biomarkers': 'EGFR Del 19, EGFR exon 21 L858R', 'raw_cancer_type': 'metastatic adenocarcinoma of the lung', 'raw_therapeutics': 'Giotrif (afatinib)'}}, {'id': 'hc:34', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 158, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [12], 'conditionQualifier_id': 13, 'subjectVariant': {}, 'therapy_id': 41, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.gleevec:0', 'document_id': 'doc:hc.gleevec', 'indication': 'GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with newly diagnosed, Philadelphia chromosome-positive, chronic myeloid leukemia (CML) in chronic phase.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved imatinib mesylate for the treatment of adult patients with newly diagnosed, Philadelphia chromosome-positive, chronic myeloid leukemia (CML) in chronic phase.', 'raw_biomarkers': 'philadelphia chromosome-positive', 'raw_cancer_type': 'chronic myeloid leukemia', 'raw_therapeutics': 'Gleevec (imatinib mesylate)'}}, {'id': 'hc:35', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 158, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [12], 'conditionQualifier_id': 13, 'subjectVariant': {}, 'therapy_id': 41, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.gleevec:1', 'document_id': 'doc:hc.gleevec', 'indication': 'GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML) in blast crisis or accelerated phase, or in chronic phase after failure of interferon-alpha therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved imatinib mesylate for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML) in blast crisis or accelerated phase, or in chronic phase after failure of interferon-alpha therapy.', 'raw_biomarkers': 'Philadelphia chromosome-positive', 'raw_cancer_type': 'chronic myeloid leukemia (CML)', 'raw_therapeutics': 'Gleevec (imatinib mesylate)'}}, {'id': 'hc:36', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 160, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [12], 'conditionQualifier_id': 0, 'subjectVariant': {}, 'therapy_id': 41, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.gleevec:2', 'document_id': 'doc:hc.gleevec', 'indication': 'GLEEVEC (imatinib mesylate) is indicated for use as a single agent for induction phase therapy in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved imatinib mesylate ', 'raw_biomarkers': 'Philadelphia chromosome-positive', 'raw_cancer_type': 'acute lymphoblastic leukemia', 'raw_therapeutics': 'Gleevec (imatinib mesylate)'}}, {'id': 'hc:37', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 160, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [12], 'conditionQualifier_id': 0, 'subjectVariant': {}, 'therapy_id': 41, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.gleevec:3', 'document_id': 'doc:hc.gleevec', 'indication': 'GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with relapsed or refractory Ph+ALL as monotherapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved imatinib mesylate for the treatment of adult patients with relapsed or refractory Ph+ALL as monotherapy.', 'raw_biomarkers': 'Philadelphia chromosome-positive', 'raw_cancer_type': 'acute lymphoblastic leukemia (Ph+ALL)', 'raw_therapeutics': 'Gleevec (imatinib mesylate)'}}, {'id': 'hc:38', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 161, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [28], 'conditionQualifier_id': 43, 'subjectVariant': {}, 'therapy_id': 41, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.gleevec:4', 'document_id': 'doc:hc.gleevec', 'indication': 'GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved imatinib mesylate for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.', 'raw_biomarkers': 'DGFR gene re-arrangements', 'raw_cancer_type': 'myelodysplastic/myeloproliferative diseases (MDS/MPD)', 'raw_therapeutics': 'Gleevec (imatinib mesylate)'}}, {'id': 'hc:39', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 162, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [29], 'conditionQualifier_id': 43, 'subjectVariant': {}, 'therapy_id': 41, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.gleevec:4', 'document_id': 'doc:hc.gleevec', 'indication': 'GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved imatinib mesylate for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.', 'raw_biomarkers': 'DGFR gene re-arrangements', 'raw_cancer_type': 'myelodysplastic/myeloproliferative diseases (MDS/MPD)', 'raw_therapeutics': 'Gleevec (imatinib mesylate)'}}, {'id': 'hc:40', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 580, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [28], 'conditionQualifier_id': 45, 'subjectVariant': {}, 'therapy_id': 41, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.gleevec:4', 'document_id': 'doc:hc.gleevec', 'indication': 'GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved imatinib mesylate for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.', 'raw_biomarkers': 'DGFR gene re-arrangements', 'raw_cancer_type': 'myelodysplastic/myeloproliferative diseases (MDS/MPD)', 'raw_therapeutics': 'Gleevec (imatinib mesylate)'}}, {'id': 'hc:41', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 581, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [29], 'conditionQualifier_id': 45, 'subjectVariant': {}, 'therapy_id': 41, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.gleevec:4', 'document_id': 'doc:hc.gleevec', 'indication': 'GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved imatinib mesylate for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.', 'raw_biomarkers': 'DGFR gene re-arrangements', 'raw_cancer_type': 'myelodysplastic/myeloproliferative diseases (MDS/MPD)', 'raw_therapeutics': 'Gleevec (imatinib mesylate)'}}, {'id': 'hc:42', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 163, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [122], 'conditionQualifier_id': 42, 'subjectVariant': {}, 'therapy_id': 41, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.gleevec:5', 'document_id': 'doc:hc.gleevec', 'indication': 'GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with aggressive sub-types of systemic mastocytosis (ASM and SMAHNMD) without the D816V c-Kit mutation.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved imatinib mesylate for the treatment of adult patients with aggressive sub-types of systemic mastocytosis (ASM and SMAHNMD) without the D816V c-Kit mutation.', 'raw_biomarkers': 'without D816V c-Kit mutation or with the c-Kit mutational status unknown', 'raw_cancer_type': 'systemic mastocytosis (ASM and SMAHNMD)', 'raw_therapeutics': 'Gleevec (imatinib mesylate)'}}, {'id': 'hc:43', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 164, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [30], 'conditionQualifier_id': 12, 'subjectVariant': {}, 'therapy_id': 41, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.gleevec:6', 'document_id': 'doc:hc.gleevec', 'indication': 'GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFR rearrangement.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved imatinib mesylate for the treatment of adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFR rearrangement.', 'raw_biomarkers': 'FIP1L1::PDGFRA rearrangement', 'raw_cancer_type': 'advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL)', 'raw_therapeutics': 'Gleevec (imatinib mesylate)'}}, {'id': 'hc:41', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 165, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [31], 'conditionQualifier_id': 22, 'subjectVariant': {}, 'therapy_id': 41, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.gleevec:7', 'document_id': 'doc:hc.gleevec', 'indication': 'GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved imatinib mesylate for the treatment of adult patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).', 'raw_biomarkers': 'Kit (CD117) positive', 'raw_cancer_type': 'unresectable and/or metastatic malignant gastrointestinal stromal tumors', 'raw_therapeutics': 'Gleevec (imatinib mesylate)'}}, {'id': 'hc:42', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067276.PDF. Revised August 2021. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': '2001-09-19', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2021-08-31', 'url': 'https://pdf.hres.ca/dpd_pm/00067276.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73824', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 165, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [31], 'conditionQualifier_id': 22, 'subjectVariant': {}, 'therapy_id': 41, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.gleevec:8', 'document_id': 'doc:hc.gleevec', 'indication': 'GLEEVEC (imatinib mesylate) is indicated for the adjuvant treatment of adult patients who are at intermediate to high risk of relapse following complete resection of Kit (CD117) positive GIST.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved imatinib mesylate for the adjuvant treatment of adult patients who are at intermediate to high risk of relapse following complete resection of Kit (CD117) positive GIST.', 'raw_biomarkers': 'Kit (CD117) positive', 'raw_cancer_type': 'gastrointestinal stromal tumors (GIST)', 'raw_therapeutics': 'Gleevec (imatinib mesylate)'}}, {'id': 'hc:43', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.herceptin', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Herceptin (trastuzumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Herceptin (trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080472.PDF. Revised May 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Herceptin', 'drug_name_generic': 'trastuzumab', 'first_published': '1999-08-13', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-05-02', 'url': 'https://pdf.hres.ca/dpd_pm/00080472.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64277', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 418, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [20], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': 25, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.herceptin:0', 'document_id': 'doc:hc.herceptin', 'indication': 'HERCEPTIN (trastuzumab for injection) is indicated for the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2, following surgery and after chemotherapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trastuzumab for the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2, following surgery and after chemotherapy.', 'raw_biomarkers': 'HER2-overexpressing', 'raw_cancer_type': 'early stage breast cancer', 'raw_therapeutics': 'Herceptin (trastuzumab)'}}, {'id': 'hc:44', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.herceptin', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Herceptin (trastuzumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Herceptin (trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080472.PDF. Revised May 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Herceptin', 'drug_name_generic': 'trastuzumab', 'first_published': '1999-08-13', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-05-02', 'url': 'https://pdf.hres.ca/dpd_pm/00080472.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64277', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.herceptin:1', 'document_id': 'doc:hc.herceptin', 'indication': 'HERCEPTIN (trastuzumab for injection) is indicated for the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2, following adjuvant chemotherapy consisting of doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trastuzumab in combination with paclitaxel or docetaxel for the treatment of early stage breast cancer patients with ECOG 0-1 status, whose tumors overexpress HER2, following adjuvant chemotherapy consisting of doxorubicin and cyclophosphamide.', 'raw_biomarkers': 'HER2 overexpression', 'raw_cancer_type': 'early stage breast cancer', 'raw_therapeutics': 'Herceptin (trastuzumab), paclitaxel, docetaxel'}, 'proposition': None}, {'id': 'hc:45', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.herceptin', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Herceptin (trastuzumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Herceptin (trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080472.PDF. Revised May 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Herceptin', 'drug_name_generic': 'trastuzumab', 'first_published': '1999-08-13', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-05-02', 'url': 'https://pdf.hres.ca/dpd_pm/00080472.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64277', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 563, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [20], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 112}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.herceptin:2', 'document_id': 'doc:hc.herceptin', 'indication': 'HERCEPTIN (trastuzumab for injection) is indicated for the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2, in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trastuzumab in combination with docetaxel and carboplatin for the treatment of early stage breast cancer patients with ECOG 0-1 status, whose tumors overexpress HER2.', 'raw_biomarkers': 'HER2 overexpression', 'raw_cancer_type': 'early stage breast cancer', 'raw_therapeutics': 'Herceptin (trastuzumab), docetaxel, carboplatin'}}, {'id': 'hc:46', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.herceptin', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Herceptin (trastuzumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Herceptin (trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080472.PDF. Revised May 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Herceptin', 'drug_name_generic': 'trastuzumab', 'first_published': '1999-08-13', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-05-02', 'url': 'https://pdf.hres.ca/dpd_pm/00080472.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64277', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 418, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [20], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': 25, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.herceptin:3', 'document_id': 'doc:hc.herceptin', 'indication': 'HERCEPTIN (trastuzumab for injection) is indicated for the treatment of patients with metastatic breast cancer (MBC) whose tumours overexpress HER2.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trastuzumab for metastatic breast cancer in patients whose tumors overexpress HER2.', 'raw_biomarkers': 'HER2-overexpressing', 'raw_cancer_type': 'metastatic breast cancer', 'raw_therapeutics': 'Herceptin (trastuzumab)'}}, {'id': 'hc:47', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.herceptin', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Herceptin (trastuzumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Herceptin (trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080472.PDF. Revised May 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Herceptin', 'drug_name_generic': 'trastuzumab', 'first_published': '1999-08-13', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-05-02', 'url': 'https://pdf.hres.ca/dpd_pm/00080472.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64277', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 351, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [20], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 65}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.herceptin:4', 'document_id': 'doc:hc.herceptin', 'indication': 'HERCEPTIN (trastuzumab for injection) can be used in combination with pertuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trastuzumab in combination with pertuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.', 'raw_biomarkers': 'HER2-positive', 'raw_cancer_type': 'metastatic breast cancer', 'raw_therapeutics': 'Herceptin (trastuzumab), pertuzumab, docetaxel'}}, {'id': 'hc:48', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.herceptin', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Herceptin (trastuzumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Herceptin (trastuzumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080472.PDF. Revised May 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Herceptin', 'drug_name_generic': 'trastuzumab', 'first_published': '1999-08-13', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-05-02', 'url': 'https://pdf.hres.ca/dpd_pm/00080472.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64277', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.herceptin:5', 'document_id': 'doc:hc.herceptin', 'indication': 'HERCEPTIN (trastuzumab for injection) in combination with capecitabine or intravenous 5-fluorouracil and cisplatin is indicated for the treatment of patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trastuzumab in combination with capecitabine or intravenous 5-fluorouracil and cisplatin for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction in patients who have not received prior anti-cancer treatment for metastatic disease.', 'raw_biomarkers': 'HER2-positive', 'raw_cancer_type': 'metastatic adenocarcinoma of the stomach or gastro-esophageal junction', 'raw_therapeutics': 'Herceptin (trastuzumab), capecitabine, 5-fluorouracil, cisplatin'}, 'proposition': None}, {'id': 'hc:49', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.ibrance', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ibrance (palbociclib) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Ibrance (palbociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080011.PDF. Revised March 2025. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Ibrance', 'drug_name_generic': 'palbociclib', 'first_published': '2016-03-15', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-03-24', 'url': 'https://pdf.hres.ca/dpd_pm/00080011.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98354', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 311, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [1, 2], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 49}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.ibrance:0', 'document_id': 'doc:hc.ibrance', 'indication': 'IBRANCE (palbociclib) is indicated for the treatment of pre/perimenopausal or postmenopausal women, or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved palbociclib in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men with HR-positive, HER2-negative locally advanced or metastatic breast cancer as initial endocrine-based therapy.', 'raw_biomarkers': 'HR-positive, HER2-negative', 'raw_cancer_type': 'locally advanced or metastatic breast cancer', 'raw_therapeutics': 'Ibrance (palbociclib), aromatase inhibitor'}}, {'id': 'hc:50', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.ibrance', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ibrance (palbociclib) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Ibrance (palbociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080011.PDF. Revised March 2025. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Ibrance', 'drug_name_generic': 'palbociclib', 'first_published': '2016-03-15', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-03-24', 'url': 'https://pdf.hres.ca/dpd_pm/00080011.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98354', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 312, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [2, 3], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 49}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.ibrance:0', 'document_id': 'doc:hc.ibrance', 'indication': 'IBRANCE (palbociclib) is indicated for the treatment of pre/perimenopausal or postmenopausal women, or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved palbociclib in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men with HR-positive, HER2-negative locally advanced or metastatic breast cancer as initial endocrine-based therapy.', 'raw_biomarkers': 'HR-positive, HER2-negative', 'raw_cancer_type': 'locally advanced or metastatic breast cancer', 'raw_therapeutics': 'Ibrance (palbociclib), aromatase inhibitor'}}, {'id': 'hc:51', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.ibrance', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ibrance (palbociclib) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Ibrance (palbociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080011.PDF. Revised March 2025. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Ibrance', 'drug_name_generic': 'palbociclib', 'first_published': '2016-03-15', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-03-24', 'url': 'https://pdf.hres.ca/dpd_pm/00080011.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98354', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 313, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [1, 2, 3], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 49}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.ibrance:0', 'document_id': 'doc:hc.ibrance', 'indication': 'IBRANCE (palbociclib) is indicated for the treatment of pre/perimenopausal or postmenopausal women, or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved palbociclib in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men with HR-positive, HER2-negative locally advanced or metastatic breast cancer as initial endocrine-based therapy.', 'raw_biomarkers': 'HR-positive, HER2-negative', 'raw_cancer_type': 'locally advanced or metastatic breast cancer', 'raw_therapeutics': 'Ibrance (palbociclib), aromatase inhibitor'}}, {'id': 'hc:52', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.ibrance', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ibrance (palbociclib) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Ibrance (palbociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080011.PDF. Revised March 2025. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Ibrance', 'drug_name_generic': 'palbociclib', 'first_published': '2016-03-15', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-03-24', 'url': 'https://pdf.hres.ca/dpd_pm/00080011.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98354', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 143, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [1, 2], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 28}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.ibrance:1', 'document_id': 'doc:hc.ibrance', 'indication': 'IBRANCE (palbociclib) is indicated for the treatment of pre/perimenopausal or postmenopausal women, or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression after prior endocrine therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved palbociclib in combination with fulvestrant for the treatment of pre/perimenopausal or postmenopausal women, or men with HR-positive, HER2-negative locally advanced or metastatic breast cancer with disease progression after prior endocrine therapy.', 'raw_biomarkers': 'HR-positive, HER2-negative', 'raw_cancer_type': 'locally advanced or metastatic breast cancer', 'raw_therapeutics': 'Ibrance (palbociclib), fulvestrant'}}, {'id': 'hc:53', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.ibrance', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ibrance (palbociclib) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Ibrance (palbociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080011.PDF. Revised March 2025. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Ibrance', 'drug_name_generic': 'palbociclib', 'first_published': '2016-03-15', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-03-24', 'url': 'https://pdf.hres.ca/dpd_pm/00080011.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98354', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 144, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [2, 3], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 28}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.ibrance:1', 'document_id': 'doc:hc.ibrance', 'indication': 'IBRANCE (palbociclib) is indicated for the treatment of pre/perimenopausal or postmenopausal women, or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression after prior endocrine therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved palbociclib in combination with fulvestrant for the treatment of pre/perimenopausal or postmenopausal women, or men with HR-positive, HER2-negative locally advanced or metastatic breast cancer with disease progression after prior endocrine therapy.', 'raw_biomarkers': 'HR-positive, HER2-negative', 'raw_cancer_type': 'locally advanced or metastatic breast cancer', 'raw_therapeutics': 'Ibrance (palbociclib), fulvestrant'}}, {'id': 'hc:54', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.ibrance', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ibrance (palbociclib) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Ibrance (palbociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080011.PDF. Revised March 2025. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Ibrance', 'drug_name_generic': 'palbociclib', 'first_published': '2016-03-15', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-03-24', 'url': 'https://pdf.hres.ca/dpd_pm/00080011.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98354', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 145, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [1, 2, 3], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 28}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.ibrance:1', 'document_id': 'doc:hc.ibrance', 'indication': 'IBRANCE (palbociclib) is indicated for the treatment of pre/perimenopausal or postmenopausal women, or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression after prior endocrine therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved palbociclib in combination with fulvestrant for the treatment of pre/perimenopausal or postmenopausal women, or men with HR-positive, HER2-negative locally advanced or metastatic breast cancer with disease progression after prior endocrine therapy.', 'raw_biomarkers': 'HR-positive, HER2-negative', 'raw_cancer_type': 'locally advanced or metastatic breast cancer', 'raw_therapeutics': 'Ibrance (palbociclib), fulvestrant'}}, {'id': 'hc:55', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.iclusig', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Iclusig (ponatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Takeda Pharmaceuticals U.S.A., Inc. Iclusig (ponatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078669.PDF. Revised February. Accessed June 2025.', 'company': 'Takeda Pharmaceuticals U.S.A., Inc.', 'drug_name_brand': 'Iclusig', 'drug_name_generic': 'ponatinib', 'first_published': '2015-03-31', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-02-24', 'url': 'https://pdf.hres.ca/dpd_pm/00078669.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92168', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 363, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [32], 'conditionQualifier_id': 13, 'subjectVariant': {}, 'therapy_id': 43, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.iclusig:0', 'document_id': 'doc:hc.iclusig', 'indication': 'ICLUSIG (ponatinib tablets) is indicated for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), or blast phase (BP) chronic myeloid leukemia (CML) for whom other tyrosine kinase inhibitor (TKI) therapy is not appropriate, including CML that is T315I mutation positive or where there is prior TKI resistance or intolerance', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved ponatinib for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) who are not appropriate for other tyrosine kinase inhibitor (TKI) therapy, including those with the T315I mutation or prior TKI resistance or intolerance.', 'raw_biomarkers': 'T315I mutation positive', 'raw_cancer_type': 'chronic myeloid leukemia (CML)', 'raw_therapeutics': 'Iclusig (ponatinib)'}}, {'id': 'hc:56', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.iclusig', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Iclusig (ponatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Takeda Pharmaceuticals U.S.A., Inc. Iclusig (ponatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078669.PDF. Revised February. Accessed June 2025.', 'company': 'Takeda Pharmaceuticals U.S.A., Inc.', 'drug_name_brand': 'Iclusig', 'drug_name_generic': 'ponatinib', 'first_published': '2015-03-31', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-02-24', 'url': 'https://pdf.hres.ca/dpd_pm/00078669.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92168', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 362, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [32, 12], 'conditionQualifier_id': 0, 'subjectVariant': {}, 'therapy_id': 43, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.iclusig:1', 'document_id': 'doc:hc.iclusig', 'indication': 'ICLUSIG (ponatinib tablets) is indicated for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) for whom other tyrosine kinase inhibitor (TKI) therapy is not appropriate, including Ph+ ALL that is T315I mutation positive or where there is prior TKI resistance or intolerance', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved ponatinib for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are not appropriate for other tyrosine kinase inhibitor (TKI) therapy, including those with the T315I mutation or prior TKI resistance or intolerance.', 'raw_biomarkers': 'Philadelphia chromosome positive, T315I mutation positive', 'raw_cancer_type': 'acute lymphoblastic leukemia (Ph+ ALL)', 'raw_therapeutics': 'Iclusig (ponatinib)'}}, {'id': 'hc:57', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.imfinzi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Imfinzi (durvalumab) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Imfinzi (durvalumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080178.PDF. Revised April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Imfinzi', 'drug_name_generic': 'durvalumab', 'first_published': '2017-11-03', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-10', 'url': 'https://pdf.hres.ca/dpd_pm/00080178.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95736', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 585, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [34, 35], 'conditionQualifier_id': 47, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 117}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.imfinzi:0', 'document_id': 'doc:hc.imfinzi', 'indication': 'IMFINZI (durvalumab) in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adult patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved durvalumab in combination with tremelimumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.', 'raw_biomarkers': 'no sensitizing EGFR mutations or ALK genomic aberrations', 'raw_cancer_type': 'metastatic non-small cell lung cancer', 'raw_therapeutics': 'Imfinzi (durvalumab), tremelimumab, platinum-based chemotherapy'}}, {'id': 'hc:58', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.imfinzi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Imfinzi (durvalumab) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Imfinzi (durvalumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080178.PDF. Revised April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Imfinzi', 'drug_name_generic': 'durvalumab', 'first_published': '2017-11-03', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-10', 'url': 'https://pdf.hres.ca/dpd_pm/00080178.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95736', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 109, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [36], 'conditionQualifier_id': 18, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 25}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.imfinzi:1', 'document_id': 'doc:hc.imfinzi', 'indication': 'Imfinzi (durvalumab) in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Imfinzi as monotherapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved durvalumab in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Imfinzi as monotherapy.', 'raw_biomarkers': 'mismatch repair deficient (dMMR)', 'raw_cancer_type': 'primary advanced or recurrent endometrial cancer', 'raw_therapeutics': 'Imfinzi (durvalumab), carboplatin, paclitaxel'}}, {'id': 'hc:59', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.iressa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Iressa (gefitinib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Iressa (gefitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060650.PDF. Revised March 2021. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Iressa', 'drug_name_generic': 'gefitinib', 'first_published': '2003-12-17', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2021-03-31', 'url': 'https://pdf.hres.ca/dpd_pm/00060650.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73040', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 147, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [10], 'conditionQualifier_id': 47, 'subjectVariant': {}, 'therapy_id': 33, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.iressa:0', 'document_id': 'doc:hc.iressa', 'indication': 'IRESSA (gefitinib) is indicated for the first line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved gefitinib for the first line treatment of patients with locally advanced (not amenable to curative therapy)or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK ', 'raw_biomarkers': 'activating mutations of EGFR', 'raw_cancer_type': 'locally advanced or metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Iressa (gefitinib)'}}, {'id': 'hc:60', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.iressa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Iressa (gefitinib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Iressa (gefitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060650.PDF. Revised March 2021. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Iressa', 'drug_name_generic': 'gefitinib', 'first_published': '2003-12-17', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2021-03-31', 'url': 'https://pdf.hres.ca/dpd_pm/00060650.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73040', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 148, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [9], 'conditionQualifier_id': 47, 'subjectVariant': {}, 'therapy_id': 33, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.iressa:0', 'document_id': 'doc:hc.iressa', 'indication': 'IRESSA (gefitinib) is indicated for the first line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved gefitinib for the first line treatment of patients with locally advanced (not amenable to curative therapy)or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK ', 'raw_biomarkers': 'activating mutations of EGFR', 'raw_cancer_type': 'locally advanced or metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Iressa (gefitinib)'}}, {'id': 'hc:61', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.iressa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Iressa (gefitinib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Iressa (gefitinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060650.PDF. Revised March 2021. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Iressa', 'drug_name_generic': 'gefitinib', 'first_published': '2003-12-17', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2021-03-31', 'url': 'https://pdf.hres.ca/dpd_pm/00060650.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73040', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 559, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [19], 'conditionQualifier_id': 47, 'subjectVariant': {}, 'therapy_id': 33, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.iressa:0', 'document_id': 'doc:hc.iressa', 'indication': 'IRESSA (gefitinib) is indicated for the first line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved gefitinib for the first line treatment of patients with locally advanced (not amenable to curative therapy)or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK ', 'raw_biomarkers': 'activating mutations of EGFR', 'raw_cancer_type': 'locally advanced or metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Iressa (gefitinib)'}}, {'id': 'hc:62', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.itovebi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Itovebi (inavolisib) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Itovebi (inavolisib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078611.PDF. Published February 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Itovebi', 'drug_name_generic': 'inavolisib', 'first_published': '2025-02-14', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-02-14', 'url': 'https://pdf.hres.ca/dpd_pm/00078611.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104427', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 510, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [1, 2, 59], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 95}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.itovebi:0', 'document_id': 'doc:hc.itovebi', 'indication': 'ITOVEBI (inavolisib film-coated tablets), in combination with palbociclib and fulvestrant, is indicated for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved inavolisib in combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.', 'raw_biomarkers': 'PIK3CA-mutated, HR-positive, HER2-negative', 'raw_cancer_type': 'locally advanced or metastatic breast cancer', 'raw_therapeutics': 'Itovebi (inavolisib), palbociclib, fulvestrant'}}, {'id': 'hc:63', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.itovebi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Itovebi (inavolisib) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Itovebi (inavolisib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078611.PDF. Published February 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Itovebi', 'drug_name_generic': 'inavolisib', 'first_published': '2025-02-14', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-02-14', 'url': 'https://pdf.hres.ca/dpd_pm/00078611.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104427', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 511, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [2, 3, 59], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 95}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.itovebi:0', 'document_id': 'doc:hc.itovebi', 'indication': 'ITOVEBI (inavolisib film-coated tablets), in combination with palbociclib and fulvestrant, is indicated for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved inavolisib in combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.', 'raw_biomarkers': 'PIK3CA-mutated, HR-positive, HER2-negative', 'raw_cancer_type': 'locally advanced or metastatic breast cancer', 'raw_therapeutics': 'Itovebi (inavolisib), palbociclib, fulvestrant'}}, {'id': 'hc:63', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.itovebi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Itovebi (inavolisib) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Itovebi (inavolisib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078611.PDF. Published February 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Itovebi', 'drug_name_generic': 'inavolisib', 'first_published': '2025-02-14', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-02-14', 'url': 'https://pdf.hres.ca/dpd_pm/00078611.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104427', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 512, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [1, 2, 3, 59], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 95}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.itovebi:0', 'document_id': 'doc:hc.itovebi', 'indication': 'ITOVEBI (inavolisib film-coated tablets), in combination with palbociclib and fulvestrant, is indicated for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved inavolisib in combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.', 'raw_biomarkers': 'PIK3CA-mutated, HR-positive, HER2-negative', 'raw_cancer_type': 'locally advanced or metastatic breast cancer', 'raw_therapeutics': 'Itovebi (inavolisib), palbociclib, fulvestrant'}}, {'id': 'hc:64', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.jemperli', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Jemperli (dostarlimab) [product monograph]. HC.', 'aliases': [], 'citation': 'GlaxoSmithKline Inc. Jemperli (dostarlimab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080289.PDF. Published April 2025. Accessed June 2025.', 'company': 'GlaxoSmithKline Inc.', 'drug_name_brand': 'Jemperli', 'drug_name_generic': 'dostarlimab', 'first_published': '2025-04-06', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-16', 'url': 'https://pdf.hres.ca/dpd_pm/00080289.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101252', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 102, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [36], 'conditionQualifier_id': 18, 'subjectVariant': {}, 'therapy_id': 47, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.jemperli:0', 'document_id': 'doc:hc.jemperli', 'indication': 'JEMPERLI (dostarlimab for injection) is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum containing regimen.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved dostarlimab as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum containing regimen.', 'raw_biomarkers': 'mismatch repair deficient (dMMR), microsatellite instability-high (MSI-H)', 'raw_cancer_type': 'recurrent or advanced endometrial cancer', 'raw_therapeutics': 'Jemperli (dostarlimab)'}}, {'id': 'hc:65', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.jemperli', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Jemperli (dostarlimab) [product monograph]. HC.', 'aliases': [], 'citation': 'GlaxoSmithKline Inc. Jemperli (dostarlimab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080289.PDF. Published April 2025. Accessed June 2025.', 'company': 'GlaxoSmithKline Inc.', 'drug_name_brand': 'Jemperli', 'drug_name_generic': 'dostarlimab', 'first_published': '2025-04-06', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-16', 'url': 'https://pdf.hres.ca/dpd_pm/00080289.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101252', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 587, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [38], 'conditionQualifier_id': 18, 'subjectVariant': {}, 'therapy_id': 47, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.jemperli:0', 'document_id': 'doc:hc.jemperli', 'indication': 'JEMPERLI (dostarlimab for injection) is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum containing regimen.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved dostarlimab as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum containing regimen.', 'raw_biomarkers': 'mismatch repair deficient (dMMR), microsatellite instability-high (MSI-H)', 'raw_cancer_type': 'recurrent or advanced endometrial cancer', 'raw_therapeutics': 'Jemperli (dostarlimab)'}}, {'id': 'hc:66', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.kadcyla', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kadcyla (ado-trastuzumab emtansine) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Kadcyla (ado-trastuzumab emtansine) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067729.PDF. Revised October 2022. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Kadcyla', 'drug_name_generic': 'ado-trastuzumab emtansine', 'first_published': '2013-09-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2022-10-13', 'url': 'https://pdf.hres.ca/dpd_pm/00067729.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89698', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 20, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [20], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': 52, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.kadcyla:0', 'document_id': 'doc:hc.kadcyla', 'indication': 'KADCYLA (trastuzumab emtansine for injection) monotherapy is indicated for the treatment of HER2-positive metastatic breast cancer patients who received both prior treatment with trastuzumab and a taxane, separately or in combination.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer patients who received both prior treatment with trastuzumab and a taxane, separately or in combination.', 'raw_biomarkers': 'HER2-positive', 'raw_cancer_type': 'metastatic breast cancer', 'raw_therapeutics': 'Kadcyla (trastuzumab emtansine)'}}, {'id': 'hc:67', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.kadcyla', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kadcyla (ado-trastuzumab emtansine) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Kadcyla (ado-trastuzumab emtansine) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067729.PDF. Revised October 2022. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Kadcyla', 'drug_name_generic': 'ado-trastuzumab emtansine', 'first_published': '2013-09-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2022-10-13', 'url': 'https://pdf.hres.ca/dpd_pm/00067729.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89698', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 20, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [20], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': 52, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.kadcyla:1', 'document_id': 'doc:hc.kadcyla', 'indication': 'KADCYLA monotherapy indicated for the adjuvant treatment of HER2-positive early breast cancer patients who have residual invasive disease following neoadjuvant taxane and trastuzumab-based treatment.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trastuzumab emtansine for the adjuvant treatment of HER2-positive early breast cancer patients who have residual invasive disease following neoadjuvant taxane and trastuzumab-based treatment.', 'raw_biomarkers': 'HER2-positive', 'raw_cancer_type': 'early breast cancer', 'raw_therapeutics': 'Kadcyla (trastuzumab emtansine)'}}, {'id': 'hc:68', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.keytruda:0', 'document_id': 'doc:hc.keytruda', 'indication': 'KEYTRUDA (pembrolizumab) is indicated for the treatment of adult patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved pembrolizumab for the treatment of adult patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor.', 'raw_biomarkers': 'BRAF V600 mutation', 'raw_cancer_type': 'unresectable or metastatic melanoma', 'raw_therapeutics': 'Keytruda (pembrolizumab)'}, 'proposition': None}, {'id': 'hc:69', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 318, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [33, 34, 35], 'conditionQualifier_id': 47, 'subjectVariant': {}, 'therapy_id': 48, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.keytruda:1', 'document_id': 'doc:hc.keytruda', 'indication': 'KEYTRUDA (pembrolizumab) as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung carcinoma (NSCLC) or stage III disease where patients are not candidates for surgical resection or definitive chemoradiation, expressing PD-L1 [Tumour Proportion Score (TPS)  1%] as determined by a validated test, with no EGFR or ALK genomic tumour aberrations.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved pembrolizumab for the first-line treatment of adult patients with metastatic non-small cell lung carcinoma (NSCLC) or stage III disease where patients are not candidates for surgical resection or definitive chemoradiation, expressing PD-L1 [Tumour Proportion Score (TPS)  1%] as determined by a validated test, with no EGFR or ALK genomic tumour aberrations.', 'raw_biomarkers': 'PD-L1 (TPS  1%), EGFR genomic tumour aberrations, ALK genomic tumour aberrations', 'raw_cancer_type': 'metastatic non-small cell lung carcinoma (NSCLC)', 'raw_therapeutics': 'Keytruda (pembrolizumab)'}}, {'id': 'hc:70', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 317, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [34, 35], 'conditionQualifier_id': 47, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 52}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.keytruda:2', 'document_id': 'doc:hc.keytruda', 'indication': 'KEYTRUDA (pembrolizumab), in combination with pemetrexed and platinum chemotherapy, is indicated for the treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumour aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved pembrolizumab in combination with pemetrexed and platinum chemotherapy for the treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumour aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC.', 'raw_biomarkers': 'no EGFR or ALK genomic tumour aberrations', 'raw_cancer_type': 'metastatic non-squamous non-small cell lung carcinoma', 'raw_therapeutics': 'Keytruda (pembrolizumab), pemetrexed, platinum chemotherapy'}}, {'id': 'hc:71', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 591, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [35, 34], 'conditionQualifier_id': 47, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 52}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.keytruda:2', 'document_id': 'doc:hc.keytruda', 'indication': 'KEYTRUDA (pembrolizumab), in combination with pemetrexed and platinum chemotherapy, is indicated for the treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumour aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved pembrolizumab in combination with pemetrexed and platinum chemotherapy for the treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumour aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC.', 'raw_biomarkers': 'no EGFR or ALK genomic tumour aberrations', 'raw_cancer_type': 'metastatic non-squamous non-small cell lung carcinoma', 'raw_therapeutics': 'Keytruda (pembrolizumab), pemetrexed, platinum chemotherapy'}}, {'id': 'hc:72', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 319, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [33], 'conditionQualifier_id': 47, 'subjectVariant': {}, 'therapy_id': 48, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.keytruda:3', 'document_id': 'doc:hc.keytruda', 'indication': 'KEYTRUDA (pembrolizumab) is indicated Keytruda as monotherapy is indicated for the treatment of adult patients with metastatic NSCLC whose tumours express PD-L1 (TPS  1%) as determined by a validated test and who have disease progression on or after platinum-containing chemotherapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved pembrolizumab as a monotherapy for treatment of adult patients with metastatic NSCLC whose tumours express PD-L1 (TPS  1%) as determined by a validated test and who have disease progression on or after platinum-containing chemotherapy.', 'raw_biomarkers': 'PD-L1 (TPS  1%)', 'raw_cancer_type': 'metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Keytruda (pembrolizumab)'}}, {'id': 'hc:73', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 323, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [36], 'conditionQualifier_id': 15, 'subjectVariant': {}, 'therapy_id': 48, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.keytruda:4', 'document_id': 'doc:hc.keytruda', 'indication': 'KEYTRUDA (pembrolizumab) is indicated, as monotherapy, for the treatment of adult patients with metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by a validated test.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved pembrolizumab as a monotherapy for the treatment of adult patients with metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by a validated test.', 'raw_biomarkers': 'MSI-H or dMMR', 'raw_cancer_type': 'metastatic colorectal cancer (CRC)', 'raw_therapeutics': 'Keytruda (pembrolizumab)'}}, {'id': 'hc:74', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 324, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [38], 'conditionQualifier_id': 15, 'subjectVariant': {}, 'therapy_id': 48, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.keytruda:4', 'document_id': 'doc:hc.keytruda', 'indication': 'KEYTRUDA (pembrolizumab) is indicated, as monotherapy, for the treatment of adult patients with metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by a validated test.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved pembrolizumab as a monotherapy for the treatment of adult patients with metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by a validated test.', 'raw_biomarkers': 'MSI-H or dMMR', 'raw_cancer_type': 'metastatic colorectal cancer (CRC)', 'raw_therapeutics': 'Keytruda (pembrolizumab)'}}, {'id': 'hc:75', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 321, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [36], 'conditionQualifier_id': 5, 'subjectVariant': {}, 'therapy_id': 48, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.keytruda:5', 'document_id': 'doc:hc.keytruda', 'indication': 'KEYTRUDA (pembrolizumab) is indicated as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours, as determined by a validated test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': '', 'raw_biomarkers': 'MSI-H or dMMR ', 'raw_cancer_type': 'unresectable or metastatic MSI-H or dMMR solid tumors', 'raw_therapeutics': 'Keytruda (pembrolizumab)'}}, {'id': 'hc:76', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 322, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [38], 'conditionQualifier_id': 5, 'subjectVariant': {}, 'therapy_id': 48, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.keytruda:5', 'document_id': 'doc:hc.keytruda', 'indication': 'KEYTRUDA (pembrolizumab) is indicated as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours, as determined by a validated test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': '', 'raw_biomarkers': 'MSI-H or dMMR ', 'raw_cancer_type': 'unresectable or metastatic MSI-H or dMMR solid tumors', 'raw_therapeutics': 'Keytruda (pembrolizumab)'}}, {'id': 'hc:77', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.keytruda:6', 'document_id': 'doc:hc.keytruda', 'indication': 'KEYTRUDA (pembrolizumab), in combination with lenvatinib, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved pembrolizumab in combination with lenvatinib for the treatment of adult patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation.', 'raw_biomarkers': 'not MSI-H or dMMR', 'raw_cancer_type': 'advanced endometrial carcinoma', 'raw_therapeutics': 'Keytruda (pembrolizumab), lenvatinib'}, 'proposition': None}, {'id': 'hc:78', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 320, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [42], 'conditionQualifier_id': 25, 'subjectVariant': {}, 'therapy_id': 48, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.keytruda:7', 'document_id': 'doc:hc.keytruda', 'indication': 'KEYTRUDA (pembrolizumab) is indicated for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) as monotherapy, in adult patients whose tumours have PD-L1 expression (Combined Positive Score [CPS]  1) as determined by a validated test.', 'initial_approval_date': '', 'initial_approval_url': ' ', 'description': 'Health Canada approved pembrolizumab for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) as monotherapy, in adult patients whose tumours have PD-L1 expression (Combined Positive Score [CPS]  1) as determined by a validated test.', 'raw_biomarkers': 'PD-L1 (CPS  1)', 'raw_cancer_type': ' metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC)', 'raw_therapeutics': 'Keytruda (pembrolizumab)'}}, {'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 325, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [20, 42], 'conditionQualifier_id': 2, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 53}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.keytruda:8', 'document_id': 'doc:hc.keytruda', 'indication': 'KEYTRUDA (pembrolizumab), in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy,is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumours express PD-L1 (Combined Positive Score [CPS] 1) as determined by a validated test.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved pembrolizumab, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumours express PD-L1 (Combined Positive Score [CPS] 1) as determined by a validated test.', 'raw_biomarkers': 'HER2-positive, PD-L1 (CPS  1)', 'raw_cancer_type': ' locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma', 'raw_therapeutics': 'Keytruda (pembrolizumab), trastuzumab, fluoropyrimidine, platinum-containing chemotherapy'}}, {'id': 'hc:77', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 327, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [2], 'conditionQualifier_id': 2, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 55}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.keytruda:9', 'document_id': 'doc:hc.keytruda', 'indication': 'KEYTRUDA (pembrolizumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved pembrolizumab, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.', 'raw_biomarkers': 'HER2-negative', 'raw_cancer_type': ' locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.', 'raw_therapeutics': 'Keytruda (pembrolizumab), fluoropyrimidine, platinum-containing chemotherapy'}}, {'id': 'hc:77', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 346, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [41, 43, 2, 44], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 63}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.keytruda:10', 'document_id': 'doc:hc.keytruda', 'indication': 'KEYTRUDA (pembrolizumab), in combination with chemotherapy, is indicated for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC), who have not received prior chemotherapy for metastatic disease and whose tumours express PD-L1 (Combined Positive Score [CPS]  10) as determined by a validated test.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved pembrolizumab, in combination with chemotherapy, for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC), who have not received prior chemotherapy for metastatic disease and whose tumours express PD-L1 (Combined Positive Score [CPS]  10) as determined by a validated test.', 'raw_biomarkers': 'PD-L1 (CPS) >= 10', 'raw_cancer_type': 'locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC)', 'raw_therapeutics': 'Keytruda (pembrolizumab), chemotherapy'}}, {'id': 'hc:77', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [product monograph]. HC.', 'aliases': [], 'citation': 'Merck Canada Inc. Keytruda (pembrolizumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080285.PDF. Published April 2025. Accessed June 2025.', 'company': 'Merck Canada Inc.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2025-04-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-11', 'url': 'https://pdf.hres.ca/dpd_pm/00080285.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94388', 'application_number': None}], 'direction': 'supports', 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.keytruda:11', 'document_id': 'doc:hc.keytruda', 'indication': 'KEYTRUDA (pembrolizumab), in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS  1) as determined by a validated test.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved pembrolizumab, in combination with chemotherapy with or without bevacizumab, for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS  1) as determined by a validated test.', 'raw_biomarkers': 'PD-L1 (CPS  1)', 'raw_cancer_type': 'persistent, recurrent, or metastatic cervical cancer', 'raw_therapeutics': 'Keytruda (pembrolizumab), chemotherapy, bevacizumab'}, 'proposition': None}, {'id': 'hc:78', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2018-03-02', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-05-31', 'url': 'https://pdf.hres.ca/dpd_pm/00075798.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 372, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [1, 2], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 77}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.kisqali:0', 'document_id': 'doc:hc.kisqali', 'indication': 'KISQALI (ribociclib tablets) is indicated, in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved ribociclib, in combination with an aromatase inhibitor, for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.', 'raw_biomarkers': 'HR+, HER2-negative', 'raw_cancer_type': 'advanced or metastatic breast cancer', 'raw_therapeutics': 'Kisqali (ribociclib), aromatase inhibitor'}}, {'id': 'hc:79', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2018-03-02', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-05-31', 'url': 'https://pdf.hres.ca/dpd_pm/00075798.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 373, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [2, 3], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 77}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.kisqali:0', 'document_id': 'doc:hc.kisqali', 'indication': 'KISQALI (ribociclib tablets) is indicated, in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved ribociclib, in combination with an aromatase inhibitor, for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.', 'raw_biomarkers': 'HR+, HER2-negative', 'raw_cancer_type': 'advanced or metastatic breast cancer', 'raw_therapeutics': 'Kisqali (ribociclib), aromatase inhibitor'}}, {'id': 'hc:80', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2018-03-02', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-05-31', 'url': 'https://pdf.hres.ca/dpd_pm/00075798.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 374, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [1, 2, 3], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 77}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.kisqali:0', 'document_id': 'doc:hc.kisqali', 'indication': 'KISQALI (ribociclib tablets) is indicated, in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved ribociclib, in combination with an aromatase inhibitor, for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.', 'raw_biomarkers': 'HR+, HER2-negative', 'raw_cancer_type': 'advanced or metastatic breast cancer', 'raw_therapeutics': 'Kisqali (ribociclib), aromatase inhibitor'}}, {'id': 'hc:81', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2018-03-02', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-05-31', 'url': 'https://pdf.hres.ca/dpd_pm/00075798.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 375, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [1, 2], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 78}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.kisqali:0', 'document_id': 'doc:hc.kisqali', 'indication': 'KISQALI (ribociclib tablets) is indicated, in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved ribociclib, in combination with an aromatase inhibitor, for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.', 'raw_biomarkers': 'HR+, HER2-negative', 'raw_cancer_type': 'advanced or metastatic breast cancer', 'raw_therapeutics': 'Kisqali (ribociclib), aromatase inhibitor'}}, {'id': 'hc:82', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2018-03-02', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-05-31', 'url': 'https://pdf.hres.ca/dpd_pm/00075798.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 376, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [2, 3], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 78}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.kisqali:0', 'document_id': 'doc:hc.kisqali', 'indication': 'KISQALI (ribociclib tablets) is indicated, in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved ribociclib, in combination with an aromatase inhibitor, for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.', 'raw_biomarkers': 'HR+, HER2-negative', 'raw_cancer_type': 'advanced or metastatic breast cancer', 'raw_therapeutics': 'Kisqali (ribociclib), aromatase inhibitor'}}, {'id': 'hc:83', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2018-03-02', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-05-31', 'url': 'https://pdf.hres.ca/dpd_pm/00075798.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 140, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [1, 2], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 27}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.kisqali:0', 'document_id': 'doc:hc.kisqali', 'indication': 'KISQALI (ribociclib tablets) is indicated, in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved ribociclib, in combination with an aromatase inhibitor, for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.', 'raw_biomarkers': 'HR+, HER2-negative', 'raw_cancer_type': 'advanced or metastatic breast cancer', 'raw_therapeutics': 'Kisqali (ribociclib), aromatase inhibitor'}}, {'id': 'hc:84', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2018-03-02', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-05-31', 'url': 'https://pdf.hres.ca/dpd_pm/00075798.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 141, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [2, 3], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 27}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.kisqali:1', 'document_id': 'doc:hc.kisqali', 'indication': 'KISQALI (ribociclib tablets) is indicated, in combination with fulvestrant for the treatment of postmenopausal women, with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved ribociclib, in combination with fulvestrant, for the treatment ostmenopausal women, with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.', 'raw_biomarkers': 'HR+, HER2-negative', 'raw_cancer_type': 'advanced or metastatic breast cancer', 'raw_therapeutics': 'Kisqali (ribociclib), fulvestrant'}}, {'id': 'hc:85', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [product monograph]. HC.', 'aliases': [], 'citation': 'Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00075798.PDF. Revised May 2024. Accessed June 2025.', 'company': 'Novartis Pharmaceuticals Canada Inc.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2018-03-02', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-05-31', 'url': 'https://pdf.hres.ca/dpd_pm/00075798.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 142, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [1, 2, 3], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 27}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.kisqali:1', 'document_id': 'doc:hc.kisqali', 'indication': 'KISQALI (ribociclib tablets) is indicated, in combination with fulvestrant for the treatment of postmenopausal women, with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved ribociclib, in combination with fulvestrant, for the treatment ostmenopausal women, with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.', 'raw_biomarkers': 'HR+, HER2-negative', 'raw_cancer_type': 'advanced or metastatic breast cancer', 'raw_therapeutics': 'Kisqali (ribociclib), fulvestrant'}}, {'id': 'hc:86', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lazcluze', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lazcluze (lazertinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Janssen Inc. Lazcluze (lazertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078792.PDF. Published March 2025. Accessed June 2025.', 'company': 'Janssen Inc.', 'drug_name_brand': 'Lazcluze', 'drug_name_generic': 'lazertinib', 'first_published': '2025-03-06', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-03-06', 'url': 'https://pdf.hres.ca/dpd_pm/00078792.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104468', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 463, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [10], 'conditionQualifier_id': 47, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 85}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lazcluze:0', 'document_id': 'doc:hc.lazcluze', 'indication': 'LAZCLUZE (lazertinib) in combination with amivantamab is indicated for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved lazertinib in combination with amivantamab for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.', 'raw_biomarkers': 'EGFR exon 19 deletions or exon 21 L858R', 'raw_cancer_type': 'locally advanced or metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Lazcluze (lazertinib), amivantamab'}}, {'id': 'hc:87', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lazcluze', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lazcluze (lazertinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Janssen Inc. Lazcluze (lazertinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078792.PDF. Published March 2025. Accessed June 2025.', 'company': 'Janssen Inc.', 'drug_name_brand': 'Lazcluze', 'drug_name_generic': 'lazertinib', 'first_published': '2025-03-06', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-03-06', 'url': 'https://pdf.hres.ca/dpd_pm/00078792.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104468', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 464, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [9], 'conditionQualifier_id': 47, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 85}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lazcluze:0', 'document_id': 'doc:hc.lazcluze', 'indication': 'LAZCLUZE (lazertinib) in combination with amivantamab is indicated for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved lazertinib in combination with amivantamab for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.', 'raw_biomarkers': 'EGFR exon 19 deletions or exon 21 L858R', 'raw_cancer_type': 'locally advanced or metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Lazcluze (lazertinib), amivantamab'}}, {'id': 'hc:88', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.libtayo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Libtayo (cemiplimab) [product monograph]. HC.', 'aliases': [], 'citation': 'Regeneron Canada Company. Libtayo (cemiplimab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078455.PDF. Revised January 2025. Accessed June 2025.', 'company': 'Regeneron Canada Company', 'drug_name_brand': 'Libtayo', 'drug_name_generic': 'cemiplimab', 'first_published': '2019-04-10', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-01-30', 'url': 'https://pdf.hres.ca/dpd_pm/00078455.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97728', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 618, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [39, 34, 35, 46], 'conditionQualifier_id': 47, 'subjectVariant': {}, 'therapy_id': 55, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.libtayo:0', 'document_id': 'doc:hc.libtayo', 'indication': 'LIBTAYO (cemiplimab for injection) is indicated as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 in  50% of tumour cells (Tumour Proportion Score [TPS]  50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved cemiplimab as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 in  50% of tumour cells (Tumour Proportion Score [TPS]  50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC.', 'raw_biomarkers': 'PD-L1 expression [Tumor Proportion Score (TPS) >= 50%] with no EGFR, ALK or ROS1 aberrations', 'raw_cancer_type': 'non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Libtayo (Cemiplimab)'}}, {'id': 'hc:89', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.libtayo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Libtayo (cemiplimab) [product monograph]. HC.', 'aliases': [], 'citation': 'Regeneron Canada Company. Libtayo (cemiplimab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078455.PDF. Revised January 2025. Accessed June 2025.', 'company': 'Regeneron Canada Company', 'drug_name_brand': 'Libtayo', 'drug_name_generic': 'cemiplimab', 'first_published': '2019-04-10', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-01-30', 'url': 'https://pdf.hres.ca/dpd_pm/00078455.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97728', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 75, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [34, 35, 46], 'conditionQualifier_id': 47, 'subjectVariant': {}, 'therapy_id': None, 'therapy_group_id': 13}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.libtayo:0', 'document_id': 'doc:hc.libtayo', 'indication': 'LIBTAYO (cemiplimab for injection) is indicated as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 in  50% of tumour cells (Tumour Proportion Score [TPS]  50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved cemiplimab as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 in  50% of tumour cells (Tumour Proportion Score [TPS]  50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC.', 'raw_biomarkers': 'PD-L1 expression [Tumor Proportion Score (TPS) >= 50%] with no EGFR, ALK or ROS1 aberrations', 'raw_cancer_type': 'non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Libtayo (Cemiplimab)'}}, {'id': 'hc:90', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lorbrena', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lorbrena (lorlatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Lorbrena (lorlatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077541.PDF. Revised October 2024. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Lorbrena', 'drug_name_generic': 'lorlatinib', 'first_published': '2019-02-20', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-10-28', 'url': 'https://pdf.hres.ca/dpd_pm/00077541.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97619', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 203, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [8], 'conditionQualifier_id': 47, 'subjectVariant': {}, 'therapy_id': 56, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lorbrena:0', 'document_id': 'doc:hc.', 'indication': 'LORBRENA (lorlatinib) is indicated as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved lorlatinib as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).', 'raw_biomarkers': 'ALK-positive', 'raw_cancer_type': 'locally advanced or metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Lorbrena (lorlatinib)'}}, {'id': 'hc:91', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lorbrena', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lorbrena (lorlatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Lorbrena (lorlatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077541.PDF. Revised October 2024. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Lorbrena', 'drug_name_generic': 'lorlatinib', 'first_published': '2019-02-20', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-10-28', 'url': 'https://pdf.hres.ca/dpd_pm/00077541.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97619', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 203, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [8], 'conditionQualifier_id': 47, 'subjectVariant': {}, 'therapy_id': 56, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lorbrena:1', 'document_id': 'doc:hc.lorbrena', 'indication': 'LORBRENA (lorlatinib) is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on crizotinib and at least one other ALK inhibitor, or patients who have progressed on ceritinib or aectinib.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved lorlatinib as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on crizotinib and at least one other ALK inhibitor, or patients who have progressed on ceritinib or aectinib.', 'raw_biomarkers': 'ALK-positive', 'raw_cancer_type': 'metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Lorbrena (lorlatinib)'}}, {'id': 'hc:92', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lumakras', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lumakras (sotorasib) [product monograph]. HC.', 'aliases': [], 'citation': 'Amgen Canada Inc. Lumakras (sotorasib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078781.PDF. Revised March 2025. Accessed June 2025.', 'company': 'Amgen Canada Inc.', 'drug_name_brand': 'Lumakras', 'drug_name_generic': 'sotorasib', 'first_published': '2021-09-09', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-03-04', 'url': 'https://pdf.hres.ca/dpd_pm/00078781.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100931', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 411, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [45], 'conditionQualifier_id': 47, 'subjectVariant': {}, 'therapy_id': 57, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lumakras:0', 'document_id': 'doc:hc.lumakras', 'indication': 'LUMAKRAS (sotorasib) is indicated for the treatment of adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C-mutated locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved sotorasib for the treatment of adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C-mutated locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy.', 'raw_biomarkers': 'KRAS p.G12C', 'raw_cancer_type': 'locally advanced or metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Lumakras (sotorasib)'}}, {'id': 'hc:93', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 258, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [48, 2], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': 46, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:0', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Patients must have confirmation of a germline BRCA mutation before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.', 'raw_biomarkers': 'deleterious or suspected deleterious gBRCAm, HER2-negative', 'raw_cancer_type': 'high risk early breast cancer', 'raw_therapeutics': 'Lynparza (olaparib)'}}, {'id': 'hc:94', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 259, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [50, 2], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': 46, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:0', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Patients must have confirmation of a germline BRCA mutation before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.', 'raw_biomarkers': 'deleterious or suspected deleterious gBRCAm, HER2-negative', 'raw_cancer_type': 'high risk early breast cancer', 'raw_therapeutics': 'Lynparza (olaparib)'}}, {'id': 'hc:95', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 258, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [48, 2], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': 46, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:1', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2- negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have progressed on or be considered inappropriate for endocrine therapy. Germline BRCA mutation must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2- negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have progressed on or be considered inappropriate for endocrine therapy.', 'raw_biomarkers': 'deleterious or suspected deleterious gBRCAm, HER2-negative', 'raw_cancer_type': 'metastatic breast cancer', 'raw_therapeutics': 'Lynparza (olaparib)'}}, {'id': 'hc:96', 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': '2025-04-29', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-04-29', 'url': 'https://pdf.hres.ca/dpd_pm/00080379.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 259, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [50, 2], 'conditionQualifier_id': 9, 'subjectVariant': {}, 'therapy_id': 46, 'therapy_group_id': None}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lynparza:1', 'document_id': 'doc:hc.lynparza', 'indication': 'LYNPARZA (olaparib) is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2- negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have progressed on or be considered inappropriate for endocrine therapy. Germline BRCA mutation must be confirmed before LYNPARZA treatment is initiated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved olaparib as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2- negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have progressed on or be considered inappropriate for endocrine therapy.', 'raw_biomarkers': 'deleterious or suspected deleterious gBRCAm, HER2-negative', 'raw_cancer_type': 'metastatic breast cancer', 'raw_therapeutics': 'Lynparza (olaparib)'}}]\n"
     ]
    }
   ],
   "source": [
    "dereference_statements1 = dereference_statements(statements, proposition_lookup, strength_lookup, indication_lookup, contribution_lookup, document_lookup)\n",
    "print(dereference_statements1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "5aedaab5-8918-40e8-8deb-c85835b497a8",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "f57b6962-a4e5-405a-adb0-26070a94c80f",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "b6960b64-3fdb-4590-a106-432eae4db194",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "moalmanac-db",
   "language": "python",
   "name": "moalmanac-db"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
